Interactions on record — worth a quick check against your medications. Check your meds →
Dietary supplement

Relora 500 mg Ingredients & Drug Interactions

by Futurebiotics

Capsule Category: Botanical
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Relora 500 mg is a dietary supplement by Futurebiotics with 2 active ingredients. Its ingredients are commonly taken for digestive complaints and diarrhea, inflammation and joint discomfort, stress and weight management (in combination products).Based on those ingredients, 1,160 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Phellodendron amurense bark extract, Magnolia officinalis bark extract. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Relora 500 mg by Futurebiotics

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Low disclosure
Ingredient Transparency · database check
Low

Most active ingredients don't disclose an individual amount — you can't tell how much of each you're getting.

Why this rating?
  • The label discloses an exact amount for 0 of its 2 active ingredients.
  • “Relora” is listed as a grouped ingredient — the label gives one combined amount (500 mg) without saying how much of each component you get.

Relora contains two active ingredients: phellodendron amurense bark extract and magnolia officinalis bark extract. Both are plant-derived materials traditionally used in herbal medicine, each contributing their own effects and interaction profile.

The product also contains several inactive ingredients — modified cellulose, microcrystalline cellulose, magnesium stearate, and silicon dioxide — which serve as binders and flow agents in the capsule.

Does it work?

Insufficient evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Insufficient

There isn't enough reliable clinical evidence to rate this product's ingredients for its stated purpose.

Why this rating?
  • The label markets this product for: stress and anxiety support.
  • We looked for evidence on: Anxiety, Stress.
  • The closest evidence on file: Magnolia is rated "Insufficient Reliable Evidence To Rate" for Anxiety (Natural Medicines).
  • Also on file: Magnolia is rated "Insufficient Reliable Evidence To Rate" for Stress.
  • Also on file: Phellodendron is rated "Insufficient Reliable Evidence To Rate" for Stress.

The evidence for what Relora actually does is thin. For phellodendron, we have insufficient reliable evidence to rate its use for acne, benign prostatic hyperplasia (enlarged prostate), diabetes, weight loss, osteoarthritis, or peptic ulcers.

Magnolia shows possibly effective evidence only for gingivitis (gum inflammation); for hay fever and anxiety, the evidence is also insufficient. In other words, while both ingredients have a traditional history, solid proof that this product works for any particular condition isn't established in the data we hold.

The evidence, ingredient by ingredient Phellodendron Magnolia

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 2 of the 2 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 2 of 2.
  • General safety write-ups exist for 2 of 2.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Human safety data for both ingredients are limited, especially with long-term use. A combination product containing these two extracts has been linked in clinical trials to occasional reports of sexual dysfunction, hand tremor, numbness around the mouth, fatigue, headache, and heartburn — though it's unclear whether phellodendron, magnolia, or another factor caused them.

Magnolia taken by mouth seems generally well tolerated overall. Regarding pregnancy and breastfeeding: phellodendron (through its berberine content) should be avoided in pregnancy and is likely unsafe during breastfeeding because berberine can pass to infants.

Magnolia is considered unsafe in pregnancy due to limited safety data and theoretical effects on the uterus, and it should also be avoided while breastfeeding.

Side effects, ingredient by ingredient Phellodendron Magnolia

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 2 of the 2 matched ingredients can interact with medications — Magnolia, Phellodendron.
  • The most serious interaction on file is rated Moderate.
  • Some involve high-stakes drug classes: anticoagulant / antiplatelet drugs; immunosuppressants / transplant drugs; diabetes medications.
  • For scale: 1,161 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before taking Relora, double-check with your doctor or pharmacist if you're on any of these: drugs processed by your liver's CYP2D6, CYP2C9, or CYP3A4 enzymes (a very large group including many antidepressants, heart medications, and others), blood pressure medications, blood thinners or antiplatelet drugs, diabetes medications or metformin, CNS depressants like sedatives or opioids, or any other regular prescription. Altogether, these interactions span 1,161 individual medications.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFormula with limited ingredient disclosure with insufficient evidence for its stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

Relora may appeal to someone looking for a plant-based approach to stress or related concerns, but solid evidence for its effectiveness isn't on file for most uses. The real caution is its interactions: if you take any prescription medication — especially heart drugs, blood thinners, diabetes medication, or anything metabolized by your liver — you need to check with your doctor or pharmacist before adding this product.

It's not safe in pregnancy or while breastfeeding.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 2 of 2 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Jan 22, 2022.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Relora 500 mg, straight from the product label.

Brand Futurebiotics
Barcode (UPC) 049479006434
Net contents 90 Vegetarian Capsule(s)
Market status On market
Date entered into DSLD Jan 22, 2022
DSLD ID 259184
Product type Botanical
Supplement form Capsule
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Vegetarian, Adult (18 - 50 Years), Women (not pregnant or lactating)
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Relora 500 mg by Futurebiotics, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
2 Vegetarian Capsule(s)
Maximum serving Sizes:
2 Vegetarian Capsule(s)
Servings per container
45
UPC/BARCODE
049479006434
IngredientAmount% DV
Phellodendron amurense bark extract0 NP--
Magnolia officinalis bark extract0 NP--
Relora500 mg--

Other ingredients: Modified Cellulose, Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Formula

Relora is an all-natural supplement that is the result of extensive review and investigation of the many plant fractions from around the world used in Traditional Chinese Medicine. This proprietary, patented formula blends specific actives from Magnolia officinalis bark and Phellodendron amurense bark extracts and has been shown to be effective in clinical research. Futurebiotics Relora provides a full 500 mg of Relora per daily serving, is a 100% vegetarian dietary supplement, and does not cause drowsiness.

500 mg of Relora per serving

FDA Disclaimer Statement

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Brand IP Statement(s)

Relora is a registered trademark of NPI, LLC. U.S. Patent No. US 6,582,735

Futurebiotics Health. Nature. Life.

General Statements

100% Satisfaction guaranteed

Formulation

100% Vegetarian

Proprietary patented extracts

FDA Statement of Identity

Dietary Supplement

Suggested/Recommended/Usage/Directions

Directions: As a dietary supplement for adults, take 2 capsules daily or as recommended by a healthcare professional.

Precautions

Do not use if you are pregnant or nursing. Do not take if currently taking any prescription medication or receiving medical treatment without consulting your healthcare professional.

Keep out of reach of children.

See for yourself

Relora 500 mg by Futurebiotics label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Relora 500 mg by Futurebiotics

These are the 2 active ingredients this product is made of. Select any to open its full monograph.

Serving size2 Vegetarian Capsule(s) Dosage formCapsule Servings per container45 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Other (inactive) ingredients: Modified Cellulose, Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide. These complete the product’s ingredient list but are not active constituents.

Interaction report

Relora 500 mg by Futurebiotics Drug Interactions

Want to check YOUR meds against Relora 500 mg?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
1,160Drugs
1,160 Moderate

Ingredients driving the most interactions

Each ingredient & the kinds of drugs it affects

For each ingredient in Relora 500 mg with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Phellodendron amurense bark extract14 drug types · 1,160 drugs

Anticoagulant/Antiplatelet Drugs

Theoretically, phellodendron might increase the risk of bleeding when used with anticoagulant or antiplatelet drugs.
Phellodendron contains berberine. In vitro and in vivo research suggest that berberine can inhibit platelet aggregation. Theoretically, phellodendron might also inhibit platelet aggregation.

Likelihood Possible Evidence D
Antidiabetes Drugs

Theoretically, phellodendron may increase the risk of hypoglycemia when taken with antidiabetes drugs.
Phellodendron contains berberine. Clinical research shows that berberine may lower blood glucose levels. Theoretically, phellodendron might also lower blood glucose levels.

Likelihood Possible Evidence D
Antihypertensive Drugs

Theoretically, phellodendron might have additive effects with antihypertensive drugs.
Phellodendron contains berberine. Animal research suggests that berberine can have hypotensive effects. Also, a clinical study suggests that taking berberine in combination with amlodipine can lower systolic and diastolic blood pressure when compared with amlodipine alone. Theoretically, phellodendron might also reduce blood pressure.

Likelihood Possible Evidence D
Cns Depressants

Theoretically, phellodendron might increase the sedative effects of CNS depressants.
Phellodendron contains berberine. Animal research suggests that berberine may have sedative effects. Theoretically, phellodendron might also have CNS depressants effects.

Likelihood Possible Evidence D
Cyclosporine (Neoral, Sandimmune)

Theoretically, phellodendron might increase blood levels of cyclosporine.
Phellodendron contains berberine. Preliminary clinical research shows that berberine can reduce metabolism of cyclosporine and increase serum levels, likely through inhibition of cytochrome P450 3A4 (CYP3A4), which metabolizes cyclosporine. Theoretically, phellodendron might also reduce the metabolism of cyclosporine.

Likelihood Possible Evidence D
Cytochrome P450 2C9 (Cyp2C9) Substrates

Theoretically, phellodendron might increase serum levels of drugs metabolized by CYP2C9.
Phellodendron contains berberine. Preliminary clinical research shows that berberine can inhibit CYP2C9. Theoretically, phellodendron might also inhibit CYP2C9.

Likelihood Possible Evidence D
Cytochrome P450 2D6 (Cyp2D6) Substrates

Theoretically, phellodendron might increase serum levels of drugs metabolized by CYP2D6.
Phellodendron contains berberine. In vitro research and preliminary clinical evidence show that berberine can inhibit CYP2D6. Theoretically, phellodendron might also inhibit CYP2D6.

Likelihood Possible Evidence D
Cytochrome P450 3A4 (Cyp3A4) Substrates

Theoretically, phellodendron might increase serum levels of drugs metabolized by CYP3A4.
Phellodendron contains berberine. In vitro research and preliminary clinical research show that berberine moderately inhibits CYP3A4. Theoretically, phellodendron might also inhibit CYP3A4.

Likelihood Possible Evidence D
Dextromethorphan (Robitussin Dm, Others)

Theoretically, phellodendron may increase serum levels of dextromethorphan.
Phellodendron contains berberine. Preliminary clinical research shows that berberine can inhibit cytochrome P450 2D6 (CYP2D6) activity and reduce the metabolism of dextromethorphan. Theoretically, phellodendron may also inhibit the metabolism of dextromethorphan.

Likelihood Possible Evidence D
Losartan (Cozaar)

Theoretically, phellodendron might reduce the therapeutic effects of losartan by decreasing its conversion to its active form.
Phellodendron contains berberine. Preliminary clinical research suggests that berberine can inhibit cytochrome P450 2C9 (CYP2C9) activity and reduce metabolism of losartan. Theoretically, phellodendron might also inhibit the metabolism of losartan.

Likelihood Possible Evidence D
Metformin (Glucophage)

Theoretically, phellodendron might increase the therapeutic and adverse effects of metformin.
Phellodendron contains berberine. In vitro and animal studies show that berberine can increase the systemic exposure and half-life of metformin, potentially increasing metformin's effects and side effects. This interaction seems to be most apparent when berberine is administered 2 hours prior to metformin. Taking berberine and metformin at the same time does not appear to increase systemic exposure to metformin. It is unclear if phellodendron might have this same effect.

Likelihood Possible Evidence D
Midazolam (Versed)

Theoretically, phellodendron might reduce metabolism of midazolam, which might increase the risk of severe adverse effects.
Phellodendron contains berberine. Preliminary clinical research shows that berberine can inhibit cytochrome P450 3A4 (CYP3A4) activity and reduce metabolism of midazolam. Theoretically, phellodendron might also inhibit the metabolism of midazolam.

Likelihood Possible Evidence D
Pentobarbital (Nembutal)

Theoretically, phellodendron might increase the sedative effect of pentobarbital.
Phellodendron contains berberine. Animal research shows that berberine can prolong pentobarbital-induced sleeping time. Theoretically, phellodendron might increase the sedative effects of pentobarbital.

Likelihood Possible Evidence D
Tacrolimus (Prograf)

Theoretically, phellodendron might increase blood levels of tacrolimus.
Phellodendron contains berberine. In a 16-year-old patient with idiopathic nephrotic syndrome who was being treated with tacrolimus 6.5 mg twice daily, intake of berberine 200 mg three times daily increased the blood concentration of tacrolimus from 8 to 22 ng/mL. Following a reduction of the tacrolimus dose to 3 mg daily, blood levels of tacrolimus decreased to 12 ng/mL. It is unclear if phellodendron might have this same effect.

Likelihood Possible Evidence D

Magnolia officinalis bark extract2 drug types · 351 drugs

Anticoagulant/Antiplatelet Drugs

Theoretically, magnolia might have additive effects and increase the risk of bleeding when used with anticoagulant or antiplatelet drugs.
In vitro research shows that the chemicals magnolol and honokiol, isolated from magnolia bark, inhibit platelet aggregation that is experimentally induced by collagen and arachidonic acid. However, they do not inhibit platelet aggregation that is induced by adenosine diphosphate, platelet-activating factor, or thrombin. This interaction has not been reported in humans.

Likelihood Possible Evidence D
Cns Depressants

Theoretically, concomitant use of large doses of magnolia bark and CNS depressants might have additive effects.
In vitro and animal research shows that constituents extracted from magnolia bark, especially honokiol and magnolol, have sedative effects. These effects may be due to the inhibition of catecholamine release and modulation of gamma-aminobutyric acid-A (GABA-A) receptors.

Likelihood Possible Evidence D
The maker

Brand information

Manufacturer and brand details for Relora 500 mg, from the product label.

Futurebiotics

See all Futurebiotics products
Name
Futurebiotics
City
Hauppauge
State
NY
ZipCode
11788
Phone Number
(800) 367-5433
Web Address
www.futurebiotics.com
Pharmacist Counseling Corner

Relora 500 mg by Futurebiotics: Common Questions

Does Relora 500 mg by Futurebiotics interact with any medications?
Yes. Based on its ingredients, Relora 500 mg has a known interaction with 1,160 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Relora 500 mg contains 2 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Can I take Relora if I'm pregnant or breastfeeding?
No — the safety data advise against it. Phellodendron should be avoided in pregnancy, and both ingredients are unsafe during breastfeeding. Talk with your doctor if you're pregnant or nursing and thinking about any herbal product.
What is phellodendron, and what does it do?
Phellodendron amurense is a plant whose bark has been used in traditional medicine. It contains berberine, a compound with sedative and blood-pressure-lowering properties in animal research. However, reliable evidence that it works for any specific condition in humans isn't established in our data.
What is magnolia officinalis, and what does it do?
Magnolia officinalis is another traditional herbal ingredient from the magnolia tree's bark. It appears possibly effective for gingivitis (inflamed gums), but for other uses like anxiety and hay fever, reliable evidence isn't available.
What side effects have been reported?
A combination product containing both these extracts has had rare reports of sexual dysfunction, trembling hands, numbness around the mouth, fatigue, and headache in clinical trials — though it's not clear whether the extracts or something else caused them. Magnolia taken by mouth is generally well tolerated.
Does Relora have any fillers or inactive ingredients?
Yes. The product contains modified cellulose, microcrystalline cellulose, magnesium stearate, and silicon dioxide as inactive ingredients — common binders and flow agents used in capsules.
Why does Relora interact with so many medications?
Phellodendron contains berberine, which can slow how your liver metabolizes drugs through three major enzyme pathways (CYP2D6, CYP2C9, and CYP3A4). Because thousands of common medications — from antidepressants to heart drugs — depend on these same pathways to be cleared from your body, that's why the interaction count is so high.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Relora 500 mg is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Relora 500 mg label
Sources

Sources & How We Checked

Relora 500 mg's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 31 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Phellodendron 22 references
  1. Chan E. Displacement of bilirubin from albumin by berberine. Biol Neonate 1993;63:201-8. PubMed
  2. Janbaz KH, Gilani AH. Studies on preventive and curative effects of berberine on chemical-induced hepatotoxicity in rodents. Fitoterapia 2000;71:25-33.. PubMed
  3. Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol 2005;61:567-72. PubMed
  4. Garrison R, Chambliss WG. Effect of a proprietary Magnolia and Phellodendron extract on weight management: a pilot, double-blind, placebo-controlled clinical trial. Altern Ther Health Med 2006;12:50-4.
  5. Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 2008;93:2559-65. PubMed
  6. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000;7:273-82. PubMed
  7. Chatterjee P, Franklin MR. Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos 2003;31:1391-7. PubMed
  8. Shanbhag, S. M., Kulkarni, H. J., and Gaitonde, B. B. Pharmacological actions of berberine on the central nervous system. Jpn.J Pharmacol 1970;20(4):482-487. PubMed
  9. Wu, J. F. and Liu, T. P. [Effects of berberine on platelet aggregation and plasma levels of TXB2 and 6-keto-PGF1 alpha in rats with reversible middle cerebral artery occlusion]. Yao Xue.Xue.Bao. 1995;30(2):98-102.
  10. Peng, W. H., Hsieh, M. T., and Wu, C. R. Effect of long-term administration of berberine on scopolamine-induced amnesia in rats. Jpn J Pharmacol 1997;74(3):261-266. DOI
  11. Sabir M and Bhide NK. Study of some pharmacological actions of berberine. Ind J Physiol & Pharmac 1971;15(3):111-132.
  12. Tripathi YB and Shukla SD. Berberis artistata inhibits PAF induced aggregation of rabbit platelets. Phytotherapy Research 1996;10:628-630.
  13. Yin, J., Xing, H., and Ye, J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008;57(5):712-717. PubMed
  14. Zhang, H., Wei, J., Xue, R., Wu, J. D., Zhao, W., Wang, Z. Z., Wang, S. K., Zhou, Z. X., Song, D. Q., Wang, Y. M., Pan, H. N., Kong, W. J., and Jiang, J. D. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin re
  15. Guo, Y., Chen, Y., Tan, Z. R., Klaassen, C. D., and Zhou, H. H. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol 2012;68(2):213-217. PubMed
  16. Wei, W., Zhao, H., Wang, A., Sui, M., Liang, K., Deng, H., Ma, Y., Zhang, Y., Zhang, H., and Guan, Y. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndro
  17. Hermann, R. and von, Richter O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med 2012;78(13):1458-1477. PubMed
  18. Chun YT, Yip TT, Lau KL, and et al. A biochemical study on the hypotensive effect of berberine in rats. Gen Pharmac 1979;10:177-182. PubMed
  19. Hou Q, Han W, Fu X. Pharmacokinetic interaction between tacrolimus and berberine in a child with idiopathic nephrotic syndrome. Eur J Clin Pharmacol 2013;69(10):1861-2. PubMed
  20. Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69-81. PubMed
  21. Kalman DS, Feldman S, Feldman R, et al. Effect of a proprietary magnolia and phellodendron extract on stress levels in healthy women: a pilot, double-blind, placebo-controlled clinical trial. Nutr J 2008;7:11.
  22. Lyu Y, Zhang Y, Yang M, et al. Pharmacokinetic interactions between metformin and berberine in rats: Role of oral administration sequences and microbiota. Life Sci. 2019;235:116818. PubMed

See these in context on the Phellodendron monograph →

Magnolia 9 references
  1. Kuribara H, Kishi E, Hattori N, et al. The anxiolytic effect of two oriental herbal drugs in Japan attributed to honokiol from magnolia bark. J Pharm Pharmacol 2000;52:1425-9. PubMed
  2. Tachikawa E, Takahashi M, Kashimoto T. Effects of extract and ingredients isolated from Magnolia obovata thunberg on catecholamine secretion from bovine adrenal chromaffin cells. Biochem Pharmacol 2000;60:433-40. PubMed
  3. Jung KY, Kim DS, Oh SR, et al. Magnone A and B, novel anti-PAF tetrahydrofuran lignans from the flower buds of Magnolia fargesii. J Nat Prod 1998;61:808-11.
  4. Garrison R, Chambliss WG. Effect of a proprietary Magnolia and Phellodendron extract on weight management: a pilot, double-blind, placebo-controlled clinical trial. Altern Ther Health Med 2006;12:50-4.
  5. Teng CM, Chen CC, Ko FN, et al. Two antiplatelet agents from Magnolia officinalis. Thromb Res 1988;50:757-65. PubMed
  6. Ghys K, De Palma A, Vandevenne A, Werbrouck J, Goossens A. Magnolia officinalis bark extract, a recently identified contact allergen in 'anti-ageing' cosmetics. Contact Dermatitis. 2015 Aug;73(2):130-2.
  7. Raison-Peyron N, Césaire A, Du-Thanh A, Dereure O. Allergic contact dermatitis caused by Magnolia officinalis bark extract in a facial anti-ageing cream. Contact Dermatitis. 2015 Jun;72(6):416-7.
  8. Nilausen TD, Johansen JD, Thyssen JP. Allergic contact dermatitis of the face caused by Magnolia officinalis bark extract. Contact Dermatitis. 2016;75(6):385-87.
  9. Amat-Samaranch V, López-Sánchez C, Tubau C, Puig L, Serra-Baldrich E. Vulvar allergic contact dermatitis caused by Magnolia officinalis bark extract. Contact Dermatitis 2022;87(1):96-97.

See these in context on the Magnolia monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring